CLLS logo

Cellectis SA (CLLS) Company Overview

Profile

Full Name:

Cellectis S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

March 24, 2015

Indexes:

Not included

Description:

Cellectis SA is a biotechnology company focused on developing innovative gene-editing therapies. They use their proprietary technology to create treatments for various diseases, particularly cancer. Cellectis aims to improve patient outcomes by harnessing the power of the immune system to target and destroy cancer cells.

Key Details

Price

$1.58

Annual Revenue

$755.00 K(-96.06% YoY)

Annual EPS

-$1.77(+24.03% YoY)

Annual ROE

-95.96%

Beta

1.09

Events Calendar

Earnings

Next earnings date:

Apr 29, 2025

Recent quarterly earnings:

Nov 4, 2024

Recent annual earnings:

Apr 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 5, 24 Barclays
Overweight
Jun 12, 24 Oppenheimer
Outperform
May 31, 24 JMP Securities
Market Outperform
Nov 1, 23 JMP Securities
Market Outperform
Aug 8, 23 Oppenheimer
Outperform
Aug 7, 23 JMP Securities
Market Outperform
Apr 5, 23 Citigroup
Buy
Mar 13, 23 Oppenheimer
Outperform
Mar 13, 23 JMP Securities
Market Outperform
Jan 19, 23 JMP Securities
Market Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Cellectis SA?
  • Does Cellectis SA pay dividends?
  • What sector is Cellectis SA in?
  • What industry is Cellectis SA in?
  • What country is Cellectis SA based in?
  • When did Cellectis SA go public?
  • Is Cellectis SA in the S&P 500?
  • Is Cellectis SA in the NASDAQ 100?
  • Is Cellectis SA in the Dow Jones?
  • When was Cellectis SA's last earnings report?
  • When does Cellectis SA report earnings?
  • Should I buy Cellectis SA stock now?

What is the ticker symbol for Cellectis SA?

The ticker symbol for Cellectis SA is NASDAQ:CLLS

Does Cellectis SA pay dividends?

No, Cellectis SA does not pay dividends

What sector is Cellectis SA in?

Cellectis SA is in the Healthcare sector

What industry is Cellectis SA in?

Cellectis SA is in the Biotechnology industry

What country is Cellectis SA based in?

Cellectis SA is headquartered in France

When did Cellectis SA go public?

Cellectis SA's initial public offering (IPO) was on March 24, 2015

Is Cellectis SA in the S&P 500?

No, Cellectis SA is not included in the S&P 500 index

Is Cellectis SA in the NASDAQ 100?

No, Cellectis SA is not included in the NASDAQ 100 index

Is Cellectis SA in the Dow Jones?

No, Cellectis SA is not included in the Dow Jones index

When was Cellectis SA's last earnings report?

Cellectis SA's most recent earnings report was on Nov 4, 2024

When does Cellectis SA report earnings?

The next expected earnings date for Cellectis SA is Apr 29, 2025

Should I buy Cellectis SA stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions